Related Experiment Video
Updated: Feb 28, 2026

01:37
A Preterm Rat Model for Pain Studies
Published on: February 9, 2024
836
Pain, Opioids, and Functional Connectivity in Preterm Infants
Caterina Coviello1, Lorenzo Frassineti2, Camilla Fazi1
1Division of Neonatology, Careggi University Hospital of Florence, 50134 Florence, Italy.
Children (Basel, Switzerland)
|February 27, 2026
Summary
Pain and opioid exposure in preterm infants can alter brain activity, impacting neurodevelopmental outcomes. Quantitative electroencephalography (EEG) measures may help predict these outcomes at 24 months corrected age.
Area of Science:
- Neonatal Neuroscience
- Developmental Pediatrics
- Clinical Neurophysiology
Background:
- Preterm infants experience significant pain and procedural burden.
- Neurodevelopmental outcomes in preterm infants remain a critical concern.
- Electroencephalography (EEG) offers a non-invasive window into brain function.
Purpose of the Study:
- To examine the effects of pain exposure on EEG features at term equivalent age (TEA).
- To determine if EEG analysis can predict neurodevelopmental outcomes at 24 months corrected age.
Main Methods:
- Studied infants born < 32 weeks gestational age without major brain injury.
- Collected data on pain exposure (procedures, opioids) and performed 8-channel EEG at TEA.
- Analyzed Brain Symmetry Index (BSI) and Circular Omega Complexity (COC) using multivariate statistics.
Main Results:
- Higher pain exposure correlated with increased BSI and decreased COC values (p < 0.05).
- Opioids like fentanyl and morphine significantly altered BSI and COC across various frequency bands (p < 0.05).
- Delta wave COC positively predicted cognitive outcomes (p = 0.034).
Conclusions:
- Pain and opioid administration may impact brain dynamics in preterm infants.
- Multivariate EEG indices show potential for characterizing neurodevelopmental outcomes.
- Quantitative EEG analysis could aid in early identification of at-risk infants.
Related Concept Videos
Analgesia and Pain Management
2.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.4K
Opioid Analgesics: Synthetic and Semisynthetic Opioids
1.2K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.2K
Opioid Analgesics: Morphine and Other Natural Cogeners
1.2K
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
1.2K
Opioid Receptors: Overview
5.4K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
5.4K

